ClinicalTrials.gg
Active, not recruitingNCT04817969TKAUpdated Sep 22, 2026

Persona Ti-Nidium Post-Market Clinical Follow-up

An interventional study of Zimmer Biomet Persona Ti-Nidium Total Knee System in Knee Pain Chronic, Osteoarthritis and Rheumatoid Arthritis, sponsored by Zimmer Biomet. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Zimmer Biomet · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 101 studies in Osteoarthritis by Zimmer Biomet — 4 open to participants now, 24 under way, none of them phase 3. Osteoarthritis · Zimmer Biomet.

Planned enrollment
16th of 48
240 · median 133
Started
2021
with 1 other
No phase
46 of 101
1 open now
Primary completion
2034-05
later than 21 of 23 live
Registered
95th of 101
by date

Among the 101 studies in Osteoarthritis by Zimmer Biomet, this one is the 16th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2021, is one of 46 with no phase, reaches primary completion later than 21 of the 23 other live ones, and was the 95th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

4 of the 101 studies in Osteoarthritis by Zimmer Biomet are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Osteoarthritis by Zimmer Biomet, or all of them as a file.
02

Study summary

The main objectives of this study are to evaluate overall clinical performance and safety of the Persona Ti-Nidium implant in total knee arthroplasty.

Read the detailed description

The study design is a prospective, multicenter data collection model of the 510(k) cleared Persona Ti-Nidium Total Knee System. The study will require each site to obtain institutional review board (IRB) approval prior to study enrollment. All potential study subjects will be required to participate in the Informed Consent Process.

All study subjects will undergo preoperative clinical evaluations prior to their total knee arthroplasty. Investigators will collect clinical data for a required 10 years. Follow-up clinical visits include Early Post-op, 6 months, 1 year, 2, 3, 5, 7 and 10 years post-operatively.

The objective of this study is to evaluate clinical performance, benefits and safety of the Persona Ti-Nidium implant in total knee arthroplasty.

Specific assessments include:

  1. Confirming the long-term safety, performance and clinical benefits of the Persona Ti-Nidium total knee system and instrumentation in primary and revision TKA.
  2. Verifying that, under normal use, the performance and clinical benefits of this device and its instrumentation conform to those intended by the manufacturer by recording patient-reported clinical outcomes measures (PROMs) and radiographic outcomes (if available).
03

Conditions studied

  • Knee Pain Chronic
  • Osteoarthritis
  • Rheumatoid Arthritis
  • Traumatic Arthritis
  • Polyarthritis
  • Varus Deformity
  • Valgus Deformity
  • Flexion Deformity of the Knee
  • Avascular Necrosis
  • Patellofemoral Osteoarthritis

Keywords

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Total Knee Arthroplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is of legal age and skeletally mature
  2. Patient is willing and able to provide written by signing and dating the IRB-approved Informed Consent document
  3. Patient is willing and able to complete scheduled follow-up evaluations as defined in the study protocol
  4. Patient qualifies for total knee arthroplasty based upon physical exam and medical history, and meets the approved indications for use of the Persona Ti-Nidium Knee System and Vivacit-E polyethylene articulating surface
  5. Independent of study participation, patient is a candidate for the commercially available Persona Ti-Nidium Knee and Vivacit-E polyethylene articulating surface, implanted in accordance with product labeling

Study Device Inclusion Criteria:

The Persona Ti-Nidium Total Knee is intended for patients with severe pain and disability due to the following:

  1. Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis.
  2. Collagen disorders, and/or avascular necrosis of the femoral condyle.
  3. Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy.
  4. Moderate valgus, varus, or flexion deformities.

Exclusion criteria

Exclusion Criteria:

  1. Patient is unwilling to sign the
  2. Patient is currently participating in any other surgical intervention or pain management study
  3. Patient is pregnant or considered a member of a protected (vulnerable) population whose inclusion in the study is inappropriate (e.g. prisoner, mentally incompetent)
  4. Patient has a mental or neurologic condition who is unwilling or incapable of following postoperative care instructions
  5. Patient has a condition which would, in the judgement of the Investigator, place the patient at undue risk or interfere with the conduct of the study
  6. Patient is institutionalized or is a known drug abuser, a known alcoholic or cannot understand the requirements of study participation

Study Device Exclusion Criteria

  1. Previous history of infection in the affected joint and/or other local/systematic infection that may affect the prosthetic joint
  2. Insufficient bone stock on femoral or tibial surfaces
  3. Skeletal immaturity
  4. Neuropathic arthropathy
  5. Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb
  6. A stable, painless arthrodesis in a satisfactory functional position
  7. Severe instability secondary to the absence of collateral ligament integrity
  8. Rheumatoid arthritis (RA) accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin
  9. The kinematic alignment surgical technique is for patients with greater than 5° valgus deformity with medial collateral ligament (MCL) insufficiency
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Other
    Persona Ti-Nidium

    Primary total knee arthroplasty subjects that receive the Zimmer Biomet Persona Ti-Nidium Total Knee System

    Device: Zimmer Biomet Persona Ti-Nidium Total Knee System

Interventions

  • DeviceZimmer Biomet Persona Ti-Nidium Total Knee System

    Primary Knee Total Arthroplasty

06

What researchers measure

Primary outcomes

  1. Oxford Knee Score (OKS)

    A patient reported functional outcome score for knee arthroplasty. This score ranges from 0-48, with higher scores indicating a better outcome.

    Time frame: 10 years

Secondary outcomes

  1. Knee Society Score (KSS) Expectations (pre and post op)

    This is a 3 question form regarding a patient's expectations of the total knee replacement. The pre-op form assesses the patient's expectations of the knee replacement, and the post-op form addresses how the replacement is meeting said expectations. The score ranges from 3-15, with higher scores indicating a better outcome.

    Time frame: 10 years

  2. EuroQol Five Dimension Five Level (EQ-5D-5L) Outcomes Measure

    A questionnaire completed by the patient and assesses his/her general health status. This score ranges from -0.573 to 1, with higher recorded scores indicating better overall health.

    Time frame: 10 years

07

Study locations

7 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for May 2034, 155 months after the start.

Of 135 industry-sponsored interventional studies with no phase under Osteoarthritis, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 81. This study's planned 155 months is above that.

Counting every sponsor, half of 711 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2021
First posted
Mar 26, 2021
StartActual
Jun 1, 2021
Primary completionEst.
May 2034
CompletionEst.
May 2034
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04817969
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
Jun 1, 2021
Primary completion
May 2034 (estimated)
Completion
May 2034 (estimated)
Last update
Sep 22, 2026

Study contacts

Hillary Overholser
study director · Zimmer Biomet Assoc Director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion